These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma. Lund B; Williamson P Obstet Gynecol; 1990 Oct; 76(4):617-22. PubMed ID: 2216190 [TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Rubin SC; Hoskins WJ; Saigo PE; Chapman D; Hakes TB; Markman M; Reichman B; Almadrones L; Lewis JL Gynecol Oncol; 1991 Aug; 42(2):137-41. PubMed ID: 1894172 [TBL] [Abstract][Full Text] [Related]
10. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501 [TBL] [Abstract][Full Text] [Related]
11. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Bolis G; Villa A; Guarnerio P; Ferraris C; Gavoni N; Giardina G; Melpignano M; Scarfone G; Zanaboni F; Parazzini F Cancer; 1996 Jan; 77(1):128-31. PubMed ID: 8630918 [TBL] [Abstract][Full Text] [Related]
12. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. Friedman RL; Eisenkop SM; Wang HJ Gynecol Oncol; 1997 Oct; 67(1):88-94. PubMed ID: 9345362 [TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Baekelandt MM; Holm R; Nesland JM; Tropé CG; Kristensen GB Anticancer Res; 2000; 20(2B):1061-7. PubMed ID: 10810398 [TBL] [Abstract][Full Text] [Related]
14. Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Bozkurt N; Yuce K; Basaran M; Kose F; Ayhan A Obstet Gynecol; 2004 Jan; 103(1):82-5. PubMed ID: 14704249 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study. Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541 [TBL] [Abstract][Full Text] [Related]
16. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gadducci A; Sartori E; Maggino T; Zola P; Landoni F; Fanucchi A; Palai N; Alessi C; Ferrero AM; Cosio S; Cristofani R Gynecol Oncol; 1998 Feb; 68(2):150-5. PubMed ID: 9514797 [TBL] [Abstract][Full Text] [Related]
17. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma. Barlow JJ; Lele SB Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408 [TBL] [Abstract][Full Text] [Related]
19. Advanced ovarian cancer patients with no evidence of disease after platinum-based chemotherapy: retrospective analysis of the role of second-look. Cacciari N; Zamagni C; Strocchi E; Pannuti F; Martoni A Eur J Gynaecol Oncol; 1999; 20(1):56-60. PubMed ID: 10422684 [TBL] [Abstract][Full Text] [Related]
20. Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer. Spirtos NM; Eisenkop SM; Schlaerth JB; Ballon SC Am J Obstet Gynecol; 2000 Jun; 182(6):1321-7. PubMed ID: 10871445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]